Confirmation of Diet as a Treatment for Gulf War Illness
NCT05675878
Gulf War Illness, Gulf War Syndrome
Washington D.C., District of Columbia, United States
View Trial DetailsNCT Number: NCT05736146
The investigators goals are to identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI. To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.
Interested in participating?
Request Info35 year and older
All sexes
Observational
Palto Alto Veterans Institute for Research, Palo Alto, California, United States
Nearly 30 years later, veterans with Gulf War Illness (GWI) continue to suffer from this persistent and debilitating illness, which remains difficult to diagnose due to the heterogeneity of clinical presentation and the complexity of biological responses to hazardous chemicals to which GW veterans were exposed during the 1990-1991 Gulf War (GW). Brain imaging studies of veterans with GWI and pre-clinical animal studies of rodents with GWI show that impaired bioenergetics and inflammation can be attributed to the atrophy of the axonal white matter tracts that link the cortical gray matter regions, and the alterations of lipid/metabolite levels. The investigators recent work shows that disturbed lipid profiles in the brain and blood after GW pesticide exposure in rodents accompany neurobehavioral and bioenergetics deficits and inflammation. The mechanisms of neurotoxicity after pesticide exposure include increases in the inactivation of lipid metabolizing enzymes. This may consequently result in accumulation of lipids in the body compartments that limit their availability for use as energy substrates, contributing to bioenergetic impairments and inflammation. These metabolic changes have also been linked to individuals who possess the apolipoprotein E (APOE) ε4 allele, a risk factor of aging related cognitive decline and neurodegenerative conditions, such as Alzheimer's disease (AD). Several studies have shown a correlation between lipid transport deficits and presence of the ε4 allele. The identification of specific lipids/metabolites and the APOE ε4 allele as important biomarkers of GWI would serve to objectively assess the brain pathology of GWI and identify subgroups of GWI based on symptom patterns and GW exposures.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2022-2024
To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids/metabolites that correlate with the CNS dysfunction in GWI.
Time frame: 2022-2024
To identify blood lipid/metabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI.
Time frame: 2022-2024
To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans.
Time frame: 2022-2024
To identify blood lipids/metabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI.
Contact information is provided by the study sponsor or research team.
Roskamp Institute Inc.
Other
Validating Blood Biomarkers of Brain Immune and Metabolic Dysfunction in Gulf War Illness
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05675878
Gulf War Illness, Gulf War Syndrome
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05355272
Adult Growth Hormone Deficiency, Bone Diseases
Houston, Texas, United States
View Trial DetailsNCT06515184
Gulf War Syndrome, Metabolic Diseases
La Jolla, California, United States
View Trial DetailsNCT07151248
Gulf War Syndrome, Neurologic Manifestations
Atlanta, Georgia, United States
View Trial Details